Santa Clara, California (March 3rd, 2015) – Crown Bioscience, Inc., a leading global drug discovery and development service company, has launched a new Life Science division specializing in in vivo and in vitro research reagents for preclinical research.

TOOLS TO SUPPORT PRECLINICAL RESEARCH, DRUG DEVELOPMENT AND VALIDATION

The first products released include in vivo grade human and mouse monoclonal antibody isotype controls and soon to be released in vivo grade monoclonal antibodies against PD-L1 and PD-1. The company will continue to expand their life science portfolio with additional antibody products as well as unique pathway reporter, neoantigen and recombinant cell lines.

“We are excited to be offering our first reagent products to support preclinical research, drug development, and product validation” says Dr. Jean-Pierre Wery, President of Crown Bioscience. “Many of these products were initially developed for our own internal needs to support some of the clinical development work we have been doing for our existing customers. Clearly we saw a need for these products and felt that making these reagents readily available would be of benefit to many of our existing customers, as well as potential customers”, says Dr. Wery.

The first reagent products are ready to ship to customers around the world. More information about Crown Bioscience’s new line of reagent products can be found atwww.crownbio.com/products

*ENDS*

For further press information please contact Crown Bioscience Inc, email:busdev@crownbio.com.

About Crown Bioscience Inc.

Founded in 2006, Crown Bioscience is a premier drug discovery and development service company providing cutting-edge translational platforms and cost effective drug discovery solutions for its biotech and pharmaceutical partners in dedicated therapeutic areas: Oncology and Metabolic Disease. Our proprietary HuPrime®, HuKemia®, HuBase™, HuMark™, HuTrial™ and HuSignature™ platforms enable unique lead optimization and translational strategies to deliver superior clinical candidates. Headquartered in Santa Clara California, Crown Bioscience has operations in China (Beijing and Jiangsu Taicang), United Kingdom (Crown Bioscience UK Ltd. in Nottingham) and the USA (North Carolina and San Diego) with business offices in Edinburgh, Boston, Karlsruhe, Milan, Phoenix, Princeton, RTP and Shanghai. For more information, please visit http://www.crownbio.com.